118 related articles for article (PubMed ID: 16890628)
1. Peginterferon alfa-2b therapy in acute hepatitis C: impact of onset of therapy on sustained virologic response.
Malnick SD; Basevitch A
Gastroenterology; 2006 Aug; 131(2):683; author reply 683-4. PubMed ID: 16890628
[No Abstract] [Full Text] [Related]
2. Peginterferon alfa-2b vs. peginterferon alfa-2a in the treatment of hepatitis C, is there any difference?
Sierra F
J Hepatol; 2007 Feb; 46(2):349; author reply 349-50. PubMed ID: 17161495
[No Abstract] [Full Text] [Related]
3. Peginterferon alfa-2b therapy in acute hepatitis C: impact of onset of therapy on sustained virologic response.
Kamal SM; Fouly AE; Kamel RR; Hockenjos B; Al Tawil A; Khalifa KE; He Q; Koziel MJ; El Naggar KM; Rasenack J; Afdhal NH
Gastroenterology; 2006 Mar; 130(3):632-8. PubMed ID: 16530503
[TBL] [Abstract][Full Text] [Related]
4. Treatment of acute hepatitis C-how to explain the differences?
Wedemeyer H; Cornberg M; Wiegand J; Jäckel E; Manns MP
Gastroenterology; 2006 Aug; 131(2):682-3; author reply 683-4. PubMed ID: 16890627
[No Abstract] [Full Text] [Related]
5. Treatment of acute hepatitis C in a child with thalassemia major using weight-based peginterferon alpha-2b.
Sharara AI; Aoun E; Koussa S; Inati A; Taher A
J Gastroenterol Hepatol; 2006 Jul; 21(7):1221. PubMed ID: 16824084
[No Abstract] [Full Text] [Related]
6. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection.
Fried MW; Shiffman ML; Reddy KR; Smith C; Marinos G; Gonçales FL; Häussinger D; Diago M; Carosi G; Dhumeaux D; Craxi A; Lin A; Hoffman J; Yu J
N Engl J Med; 2002 Sep; 347(13):975-82. PubMed ID: 12324553
[TBL] [Abstract][Full Text] [Related]
7. Peginterferon alfa-2b treatment for patients affected by acute hepatitis C: presentation of six case reports.
Scotto G; Palumbo E; Fazio V; Cibelli DC; Saracino A; Angarano G
Infection; 2005 Feb; 33(1):30-2. PubMed ID: 15750757
[TBL] [Abstract][Full Text] [Related]
8. Effect of ribavirin on hepatitis C viral kinetics in patients treated with pegylated interferon.
Herrmann E; Lee JH; Marinos G; Modi M; Zeuzem S
Hepatology; 2003 Jun; 37(6):1351-8. PubMed ID: 12774014
[TBL] [Abstract][Full Text] [Related]
9. Viral kinetics in genotype 1 chronic hepatitis C patients during therapy with 2 different doses of peginterferon alfa-2b plus ribavirin.
Buti M; Sanchez-Avila F; Lurie Y; Stalgis C; Valdés A; Martell M; Esteban R
Hepatology; 2002 Apr; 35(4):930-6. PubMed ID: 11915041
[TBL] [Abstract][Full Text] [Related]
10. Pegylated interferon alpha-2b in patients with acute hepatitis C.
Mukhopadhyay A
Natl Med J India; 2006; 19(4):201-2. PubMed ID: 17100108
[No Abstract] [Full Text] [Related]
11. Peginterferon alfa-2a/ribavirin in hepatitis C virus patients nontolerant or nonresponsive to peginterferon alfa-2b/ribavirin.
Rustgi VK; Esposito S; Hamzeh FM; Shiffman ML
Aliment Pharmacol Ther; 2008 Mar; 27(5):433-40. PubMed ID: 18081737
[TBL] [Abstract][Full Text] [Related]
12. A randomized, double-blind trial comparing pegylated interferon alfa-2b to interferon alfa-2b as initial treatment for chronic hepatitis C.
Lindsay KL; Trepo C; Heintges T; Shiffman ML; Gordon SC; Hoefs JC; Schiff ER; Goodman ZD; Laughlin M; Yao R; Albrecht JK;
Hepatology; 2001 Aug; 34(2):395-403. PubMed ID: 11481625
[TBL] [Abstract][Full Text] [Related]
13. Pegylated interferon alfa-2b vs standard interferon alfa-2b, plus ribavirin, for chronic hepatitis C in HIV-infected patients: a randomized controlled trial.
Carrat F; Bani-Sadr F; Pol S; Rosenthal E; Lunel-Fabiani F; Benzekri A; Morand P; Goujard C; Pialoux G; Piroth L; Salmon-Céron D; Degott C; Cacoub P; Perronne C;
JAMA; 2004 Dec; 292(23):2839-48. PubMed ID: 15598915
[TBL] [Abstract][Full Text] [Related]
14. [Genotype 1 superresponder treat for only 24 weeks].
MMW Fortschr Med; 2005 Dec; 147(51-52):69. PubMed ID: 16402717
[No Abstract] [Full Text] [Related]
15. Economic impact of extended treatment with peginterferon alpha-2a and ribavirin for slow hepatitis C virologic responders.
Nakamura J; Toyabe SI; Aoyagi Y; Akazawa K
J Viral Hepat; 2008 Apr; 15(4):293-9. PubMed ID: 18307591
[TBL] [Abstract][Full Text] [Related]
16. Early HCV RNA changes in patients with chronic hepatitis C treated with peginterferon alfa 2b and ribavirin.
Gallegos-Orozco JF; Fuentes AP; Olivera-Martinez MA; Gutiérrez-Reyes G; Cortina D; Oregel JA; Pérez-Pruna C; Sixtos MS; Cruz-Castellanos S; Soto-Ramírez LE; Rodríguez-Díaz R; Fuentes-Romero L; Gutiérrez-Ruiz MC; Kershenobich D
Rev Invest Clin; 2003; 55(2):138-42. PubMed ID: 12827916
[TBL] [Abstract][Full Text] [Related]
17. Peginterferon alfa-2b and weight-based or flat-dose ribavirin in chronic hepatitis C patients: a randomized trial.
Jacobson IM; Brown RS; Freilich B; Afdhal N; Kwo PY; Santoro J; Becker S; Wakil AE; Pound D; Godofsky E; Strauss R; Bernstein D; Flamm S; Pauly MP; Mukhopadhyay P; Griffel LH; Brass CA;
Hepatology; 2007 Oct; 46(4):971-81. PubMed ID: 17894303
[TBL] [Abstract][Full Text] [Related]
18. A randomised trial to compare the pharmacokinetic, pharmacodynamic, and antiviral effects of peginterferon alfa-2b and peginterferon alfa-2a in patients with chronic hepatitis C (COMPARE).
Silva M; Poo J; Wagner F; Jackson M; Cutler D; Grace M; Bordens R; Cullen C; Harvey J; Laughlin M
J Hepatol; 2006 Aug; 45(2):204-13. PubMed ID: 16780997
[TBL] [Abstract][Full Text] [Related]
19. Successful pegylated interferon alpha2a monotherapy for hepatitis C virus infection in a transplanted patient who relapsed after the preceding course.
Ichikawa T; Taura N; Miyaaki H; Matsuzaki M; Eguchi S; Takatsuki M; Kanematsu T; Nakao K
Transpl Infect Dis; 2011 Aug; 13(4):438-40. PubMed ID: 21309967
[No Abstract] [Full Text] [Related]
20. Pegylated interferon alpha therapy in acute hepatitis C: relation to hepatitis C virus-specific T cell response kinetics.
Kamal SM; Ismail A; Graham CS; He Q; Rasenack JW; Peters T; Tawil AA; Fehr JJ; Khalifa Kel S; Madwar MM; Koziel MJ
Hepatology; 2004 Jun; 39(6):1721-31. PubMed ID: 15185314
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
